DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Reminyl (Galantamine Hydrobromide) - Summary

 
 



REMINYL SUMMARY

REMINYL® (galantamine hydrobromide) is a reversible, competitive acetylcholinesterase inhibitor.

REMINYL® (galantamine hydrobromide) is indicated for the treatment of mild to moderate dementia of the Alzheimer's type.


See all Reminyl indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Reminyl (Galantamine)

DBS May Slow Cognitive Decline in Alzheimer's Disease
Source: Medscape Psychiatry & Mental Health Headlines [2016.07.22]
In a phase 2 study in patients with mild Alzheimer's disease, deep brain stimulation of the fornix increased the brain's ability to metabolize glucose and, in some cases, may slow cognitive decline.
Medscape Medical News

Promising new methods for early detection of Alzheimer's disease
Source: Medical Devices / Diagnostics News From Medical News Today [2016.07.08]
New methods to examine the brain and spinal fluid heighten the chance of early diagnosis of Alzheimer's disease.

FAQ: What Is Early-Onset Alzheimer's Disease?
Source: MedicineNet Dementia Specialty [2016.07.08]
Title: FAQ: What Is Early-Onset Alzheimer's Disease?
Category: Health News
Created: 7/8/2016 12:00:00 AM
Last Editorial Review: 7/8/2016 12:00:00 AM

Study shows effectiveness of brief, simple test to screen for cognitive impairment in Alzheimer's disease
Source: Medical Devices / Diagnostics News From Medical News Today [2016.07.07]
For the first time, researchers have determined that a brief, simple number naming test can differentiate between cognitively healthy elderly individuals and cognitively impaired people with...

Alzheimer's Disease Symptoms and Early Signs
Source: MedicineNet memantine Specialty [2016.06.24]
Title: Alzheimer's Disease Symptoms and Early Signs
Category: Slideshows
Created: 9/21/2015 12:00:00 AM
Last Editorial Review: 6/24/2016 12:00:00 AM

more news >>

Published Studies Related to Reminyl (Galantamine)

Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. [2014]
rivastigmine, and memantine for the treatment of AD... CONCLUSIONS: Cholinesterase inhibitors and memantine are able to stabilize or

The prediction of response to galantamine treatment in patients with mild to moderate Alzheimer's disease. [2014]
The prediction of efficacy in long-term treatment of acetylcholinesterase inhibitors (AChEIs) is a major clinical issue, although no consistently strong predictive factors have emerged thus far... Patients who show improvement of episodic memory function during the first 4 weeks of galantamine administration may be likely to particularly benefit from galantamine treatment.

Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease. [2011.03]
BACKGROUND: This analysis aimed to identify an operational, clinically relevant definition of response achieved in short-term clinical trials to support the identification of patients with Alzheimer's disease (AD) who would benefit most from long-term galantamine therapy... CONCLUSIONS: Patients who demonstrate improvement, stability, or limited cognitive decline 2-5 months after reaching maintenance doses of galantamine are more likely to experience continued benefit from long-term galantamine therapy.

Galantamine improves sustained attention in chronic cocaine users. [2011.02]
Chronic cocaine users are known to have cognitive deficits that are predictive of poor treatment response. Whether these deficits improve with medications targeting specific cognitive functions has not been examined in previous studies.

Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. [2011.02]
CONCLUSION: Galantamine showed no ameliorative effects on cognitive measures in this 6month, double-blind study of patients with schizophrenia treated with an assured and stable antipsychotic medication delivery system. Galantamine may not be an appropriate augmentation agent for cognitive impairments in patients with schizophrenia at the dose used. Copyright (c) 2010 Elsevier B.V. All rights reserved.

more studies >>

Clinical Trials Related to Reminyl (Galantamine)

Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions [Completed]
The objective of this study was to compare the rate and extent of absorption of Purepac, a subsidiary of Alpharma Inc., U. S.A., galantamine and Janssen Pharmaceutica Products, L. P., U. S.A. (Reminyl),galantamine, administered as a 1 x 4 mg tablet, under fed conditions.

Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions [Completed]
The objective of this study was to compare the rate and extent of absorption of Purepac, a subsidiary of Alpharma Inc., U. S.A., galantamine and Janssen Pharmaceutica Products, L. P., U. S.A. (Reminyl),galantamine, administered as a 1 x 4 mg tablet, under fasting conditions.

Galantamine Bioequivalence Study of Dr. Reddy's Under Fasting Condition [Completed]

Galantamine Bioequivalence Study of Dr. Reddy's Under Fed Condition [Completed]

A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease [Completed]
The purpose of this study is to demonstrate that the change of attention measure is correlated with the changes of caregiver's burden after treatment with galantamine.

more trials >>


Page last updated: 2016-07-22

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015